Abstract

This study aims to report the correlation of MTHFR gene mutation with the genesis of depression and antidepressants non-response in a patient, highlighting the importance of genetic investigation and indicating the replacement of L-methylfolate as an effective treatment adjuvant. This is a case report of a patient diagnosed with major depressive disorder, refractory to pharmacological therapies, in monotherapy or combination therapy, and psychotherapy. After 1 year and 4 months of persistent residual symptoms, genetic testing of the MTHFR gene was requested with confirmation of a heterozygous double mutation of MTHFR. This gene polymorphism can result in deficiency of L-methylfolate, which is related to psychiatric diseases and refractoriness to antidepressant therapy. With the introduction of l-methylfolate 15mg, the patient reported remission of depressive symptoms in 4 months of follow-up. MTHFR gene mutations influence the action of folate, favoring depression and leading to refractory response to conventional treatment.

Keywords

  • Depressive Disorder
  • Treatment-Resistant
  • Folic acid-therapeutic use
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Methylation
  • Biopterin/metabolism

References

  1. Jiang, W., Xu, J., Lu, X. J., & Sun, Y. (2016). Association between MTHFR C677T polymorphism and depression: a meta-analysis in the Chinese population. Psychology, health & medicine, 21(6), 675–685. https://doi.org/10.1080/13548506.2015.1120327
  2. Jha, S., Kumar, P., Kumar, R., & Das, A. (2016). Effectiveness of add-on l-methylfolate therapy in a complex psychiatric illness with MTHFR C677 T genetic polymorphism. Asian journal of psychiatry, 22, 74–75. https://doi.org/10.1016/j.ajp.2016.05.007
  3. Do Prado CM, Dieckmann LHJ, Dieckmann PM. Farmacogenética na psiquiatria: entendendo os princípios e a aplicabilidade clínica. Rio de Janeiro: DOC Content; 2018.
  4. Oberg, E., Givant, C., Fisk, B., Parikh, C., & Bradley, R. (2015). Epigenetics in Clinical Practice: Characterizing Patient and Provider Experiences with MTHFR Polymorphisms and Methylfolate. Journal of nutrigenetics and nutrigenomics, 8(3), 137–150. https://doi.org/10.1159/000440700
  5. Mech, A. W., & Farah, A. (2016). Correlation of clinical response with homocysteine reduction during therapy with reduced B vitamins in patients with MDD who are positive for MTHFR C677T or A1298C polymorphism: a randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry, 77(5), 668–671. https://doi.org/10.4088/JCP.15m10166
  6. Bjelland, I., Tell, G. S., Vollset, S. E., Refsum, H., & Ueland, P. M. (2003). Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Archives of general psychiatry, 60(6), 618–626. https://doi.org/10.1001/archpsyc.60.6.618
  7. Wan, L., Li, Y., Zhang, Z. et al. Methylenetetrahydrofolate reductase and psychiatric diseases. Transl Psychiatry 8, 242 (2018). https://doi.org/10.1038/s41398-018-0276-6
  8. Gabriela Nielsen, M., Congiu, C., Bortolomasi, M., Bonvicini, C., Bignotti, S., Abate, M., Milanesi, E., Conca, A., Cattane, N., Tessari, E., Gennarelli, M., & Minelli, A. (2015). MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. Journal of affective disorders, 183, 179–186. https://doi.org/10.1016/j.jad.2015.05.003
  9. Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., Baer, L., Dalton, E. D., Sacco, G. R., Schoenfeld, D., Pencina, M., Meisner, A., Bottiglieri, T., Nelson, E., Mischoulon, D., Alpert, J. E., Barbee, J. G., Zisook, S., & Fava, M. (2012). L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. The American journal of psychiatry, 169(12), 1267–1274. https://doi.org/10.1176/appi.ajp.2012.11071114